Business Wire

DENTAL-MONITORING

16.3.2020 19:13:09 CET | Business Wire | Press release

Share
Photo Monitoring Light And SmileMate Virtual Consultation

Dental Monitoring tele dentistry solutions allow dental professionals to connect with their patients remotely and in a HIPAA compliant manner. Our unique technology enables dentists and orthodontists to assess, monitor treatment, and communicate with their patients as much as needed, even when they are at home.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005750/en/

Given the unprecedented situation we are facing worldwide, and with patient access to practices becoming more difficult, Dental Monitoring’s priorities have shifted to supporting all dental professionals whoever and wherever they are, to continue the care of their patients, as well as ensuring the continuity of their practices. Our current solutions use the full extent of our AI engine, and complete onboarding for practices can often take a few weeks to integrate fully. Therefore we have decided to refocus our company priorities to launch immediately two new “Light ” versions of our existing solutions. These new versions will be simpler and more immediate to implement for these times - rapid on-boarding and roll-out to all patients:

Photo Monitoring Light :
Simplified at-home monitoring platform with instant two-way communication with patients.
Capturing pictures of the mouth through the DM App allowing doctors to :

  • Evaluate remotely their patients' current oral situation or treatment progress as if they were in the practice
  • Have two way communication and guidance between doctor and patient
  • Send annotated pictures directly via the patient App so patients can better understand their doctor’s guidance.

Photo Monitoring Light will also enable the clinical team to request an immediate DM scan when a patient requests immediate feedback, so that the doctor can better evaluate the patient’s situation and advise accordingly.

To implement Photo Monitoring Light: please visit https://dental-monitoring.com/maintain-patient-care/

SmileMate Virtual Consultation:
Remote assessment of new and existing patients.
All patient calls can be pre-qualified remotely using the SmileMate assessment tool directly through doctors practice websites.

The process is simple:
Step 1- The patient clicks on the widget on the doctor’s website, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an app or use cheek retractors)
Step 2- A comprehensive customized report and treatment option is automatically generated by our AI engine and sent to the doctor
Step 3- Doctors qualify the patient’s needs on their SmileMate portal
Step 4- Doctors customize and share the report with the patient with advice or a booking link.

To implement SmileMate Virtual Consultation please visit: https://dental-monitoring.com/maintain-patient-care/

Fast-Track Accelerated On-Boarding.
Photo Monitoring Light and SmileMate Virtual Consultation are ready for use in minutes after doctors and their teams have performed our free fast-track accelerated training. Implementing fast-track onboarding into dental practices is simplified through our new streamlined process, which is done 100% remotely through webinars by our customer support team.
Call us or visit: https://dental-monitoring.com/maintain-patient-care/ to book a time slot for our next training session.

Opening up a dedicated 24/7 hotline to answer any questions or needs during the pandemic.
Our priority has always been our customers and their patients. Over the next few months, we will be solely focused on delivering solutions that can help doctors maintain the expert care they provide to their patients. To that extent, and during the pandemic, we will maximize accessibility to our solutions by reducing our price on these new solutions by 50% :

  • Photo Monitoring Light will be accessible for US$3 per month/patient monitored
  • For SmileMate Virtual Consultation will be at US$150/month for 50 unique patient scans

We have also directed our worldwide sales force to focus 100% on Customer Service - working side by side with doctors to help treat their patients remotely.

About Dental Monitoring (www.dental-monitoring.com )
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States, and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye